Could treating asthma help rhinitis?

Clinical and Experimental Allergy

Volumn 27, Issue 12, 1997, Pages 1387-1393

  Scadding, G K ^a  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; ASTHMA; BRONCHOSPASM; HEALTH CARE COST; HUMAN; NOSE BREATHING; PRIORITY JOURNAL; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0031465572     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.1997.tb02982.x     Document Type: Review

References (86)

1. Bryce FP, Neville RE, Crombie IK et al, Controlled trial of an audit facilitator in diagnosis and treatment of childhood asthma in general practice. Br Med J 1995: 310:838-42.
2. Sibbald B. Epidemiology of allergic rhinitis. In: Monograph on epidemiology of allergic disease (ed) Burr HL. Basle, S Karger 1993: 61-79.
3. Bousquet J. A physician's view of health economics in asthma. Eur Respir Rev 1995; 5:275-8.
4. Settipane RJ, Hagy GW, Settipane GA. Long term risk factors for developing asthma and allergic rhinitis: a 23 year follow up of college students. Allergy Proc 1994; 15:215.
5. Eggleston PA. Upper inflammatory diseases and bronchial hyperresponsiveness. J Allergy Clin Immunol 1988; 81:1036-41.
6. Scadding GK. The co-existence of upper and lower airways disease. Resp Dis in Practice 1994; 11:18-20.
7. Brydon MJ. Patient audit for allergy, asthma and rhinitis. Asthma J 1996; 29-32.
8. Djukanovic R, Wilson SJ, Howarth PH. Pathology of rhinitis and bronchial asthma. Clin Exp Allergy 1996; 26 (Suppl.3):44-51.
9. Beasley R et al. Pathology of asthma and its clinical implications. J Allergy Clin Immunol 1993; 92:148-54.
10. Creticos PS. Allergic Rhinitis. In: Asthma and Rhinitis (eds) Busse WW, Holgate ST. Blackwell Science 1995: 1394-414.
11. Persson CGA, Svensson C, Greiff Let al. The use of the nose to study the inflammatory response of the respiratory tract. Thorax 1992; 47:993-1000.
12. Bonavia M, Crimi E, Quaglia A, Brusasco V. Comparison of early and late asthmatic responses between patients with allergic rhinitis and mild asthma. Eur Respir J 1996; 9:905-9.
13. Bahmer FA. Topical levocabastine - an effective alternative to oral antihistamines in seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 1995; 25:220-7.
14. 1 drugs in mild asthma. Allergy 1995; 50:41-7.
15. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. National Heart, Lung, and blood Institute. 95-3659 January 1995.
16. Rhinitis Management Guidelines; British Society for Allergy and Clinical Immunology ENT, sub-committee 1995:1-32.
17. Fokkens W. The influence of intranasal steroids on the pathogenesis of allergic rhinitis. Paper presented at 2nd Symposium on Experimental Rhinology and Immunology of the Nose, Rotterdam, 1996.
18. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148:S1-26.
19. Scadding GK. Chronic non-infectious, non-allergic rhinitis. Prescriber's J 1996; 36:93-101.
20. Packe GE, Robb O, Robins SP et al. Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclamethasone dipropionate. J R Coll Phys Lond 1996; 30:128-32.
21. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance with treatment in asthma. Eur Respir J 1995; 8:899-904.
22. Altounyan REC, Howell JBL. Treatment of asthma with disodium cromoglycate (FPL70, 'Intal'). Respiration Supplement 1969; 26:131-40.
23. Lenney W, Wells NEJ, O'Neill BA. The burden of paediatric asthma. Eur Respir Rev 1994; 4:49-62.
24. Whiteman IA, Gaduzo SC. The management of mild-to-moderate asthmatics in general practice: a retrospective analysis. Br J Med Economics 1993; 6:25-35.
25. Jolicouer LM, Boyer JG, Reeder CE, Turner J. Influence of asthma or allergies on the utilization of health care resources and quality of life of college students. J Asthma 1994; 31:251-67.
26. Meltzer EO. Evaluating rhinitis: clinical, rhinomanometric and cytologic assessments. J Allergy Clin Immunol 1988; 82:900-8.
27. Jones PW. Quality of life, health economics and asthma. Eur Respir Rev 1995; 5:279-83.
28. Bousquet J, Knani J, Dhivert H et al. Quality of life in asthma. Internal consistency and validity of the SF-36 questionnaire. Am J Resp Crit Care Med 1994; 149:371-5.
29. Bousquet J, Bullinger M, Fayol C el al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J All Clin Immunol 1994; 94:182-8.
30. Rutten-van-Molken MPMH. van Doorslaer EKA, Jansen MCC et al. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151:975-82.
31. Bryan J. How much does asthma cost? Costs and options in asthma. 1995; 1:4-6.
32. Pearce N, Beasley R, Crane J et al. End of the new Zealand asthma mortality epidemic. Lancet 1995; 345:41-4.
33. Adelroth E, Rosenhall L. Glennon C. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics: a two year study. Allergy 1985; 40:58-64.
34. Durham SR. British Thoracic Society Asthma Guidelines Review. Allergen avoidance measures. Resp Med 1996; 90:441-5.
35. van Velzen E, van den Bos J-W, Benckhuijsen JAW et al. Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. Thorax 1996; 51:582-4.
36. Peat JK. Prevention measures of asthma. Eur Respir J 1996; 9:1545-55.
37. Coloff MJ, Ayres J, Carswell F et al. The control of allergens of house dust mites and domestic pets. A position paper. Clin Exp Allergy 1992; 22:1-28 (Suppl.).
38. Howarth PH, Lunn A, Tomkins S. Bedding barrier intervention in house dust mite respiratory allergy. Poster and abstract presented at BASCI annual conference, September 1991:63.
39. Coloff MJ, Taylor C, Merrett TG. The use of domestic steam treatment for the control of house dust mites. Clin Exp Allergy 1995; 25:1061-6.
40. Warner JO, Gotz M, Landau LI et al. Management of asthma: a consensus statement. Arch Dis Child 1989; 57:1065-79.
41. Cochrane GM. Compliance in asthma: a European perspective. Eur Respir Rev 1995; 5:116-9.
42. Cochrane GM. Give patient compliance. Costs and options in asthma. 1:22-6.
43. James PNE, Anderson JB, Prior JG et al. Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J 1985; 61:7-10.
44. Dompeling E, Vansgrunsven PM. Van Schayckn CP et al. Treatment with inhaled steroids in asthma and chronic bronchitis: long term compliance with inhaler technique. Fam Pract 1992; 92:161-6.
45. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patient's compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-52.
46. Sullivan P, Bekir S, Juffar Z et al. Antiinflammutory effects of low-dose oral theophylline in atopic asthma. Lancet 1994; 343:1006-8.
47. Naclerio R, Bartenfelder D, Proud D et al. Theophylline reduces histamine release during pollen induced rhinitis. J Allergy Clin Immunol 1986; 78:874-6.
48. Baker MD. Theophylline toxicity in children. J Pediatr 1986; 109:538-47.
49. Spector S. Data presented at World Allergy Conference, New York. October 1996.
50. Aubier M. Data presented at World Allergy Conference, New York. October 1996.
51. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76:440-6.
52. Grant JA, Nicodemus CF, Findlay SR et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective randomized, placebo-controlled trial. J Allergy Clin Immunol 1995; 95:923-32.
53. Naclerio RM et al. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis 1991; 143:S91-S96.
54. Harris RR, Carter GW, Bell RL et al. Clinical activity of leukotriene inhibitors. Int J Immunopharmac 1995; 17:147-56.
55. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30:121-45.
56. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammations. Science 1983; 220:568-75.
57. Tauber AI, Kaliner M, Stechschulte DJ, Austen KF. Immunologic release of histamine and slow reacting substance of anaphylaxis from human lung. V. Effects of Prostaglandins on release of histamine. J Immunol 1973; 111:27-32.
58. 4. Proc Natl Acad Sci USA 1983; 80:1712-6.
59. 4-like immunoreactivity in tear fluid from subjects challenged with specific allergen. Prostaglandins 1984; 27:369-74.
60. Creticos PS, Peters SP, Adkinson NF Jr et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310:1626-30.
61. Shaw RJ, Fitzharris P, Cromwell O, et al. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB, in allergic rhinitis. Allergy 1985; 40:1-6.
62. 4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136:357-62.
63. Lewis RA. Mast cell-dependent immediate hypersensitivity responses. Prog Clin Biol Res 1986; 213:457-70.
64. 4) in human skin. J Invest Dermatol 1983; 80:115-9.
65. Weiss JW, Drazen JM, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216:196-8.
66. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126:449-51.
67. 4 increases nasal blood flow in humans. Prostaglandins 1984; 27:599-604.
68. Ford-Hutchinson AW, Bray MA, Doig MV, et al. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286:264-5.
69. 4 and the role of polymorphonuclear leukocytes. Inflammation 1982; 6:189-200.
70. Cashman JR, Oliva SL. Leukotriene biosynthesis inhibitors and leukotriene receptor antagonists. Drugs of Today 1988; 24:723-32.
71. Israel E, Rubin P, Kemp P et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119:1059-106.
72. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323:1740-8.
73. Howarth PH, Harrison K, Lau L et al. The influence of 5-lipoxygenase inhibitor A-78773 on the nasal response to allergen in rhinitis. J Allergy Clin Immunol 1994; 93:297.
74. Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of ICI, 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:S83-6.
75. Grossman J, Tucson AZ, Bronsky E et al. A multicenter, double-blind, placebo-controlled study to evaluate the safety, tolerability and clinical activity of oral, twice-daily ITA, Pranlukast (SB205312) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95 (1:part 2):Abs 846.
76. Wisniewski PL, Busse WW, Meltzer SS et al. Bronchodilatory effects of BAYx7195, a selective leukotriene receptor antagonist. J Allergy Clin Immunol 1995; 95 (1:part 2): Abs 639.
77. Reiss TF, Altman LC, Munk ZM. MK-0476, an LTD4 receptor antagonist improves the signs and symptoms of asthma with a dose as low as 10 mg once daily. Am J Respir Crit Care Med 1994, 151 (4 part; 2):A378.
78. Welch MJ, Nelson HS, Paull BR et al. Effect of RG12525, a new leukotriene antagonist on pulmonary function of asthmatic adults. Ann Allergy 1994; 72:348-52.
79. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI, 204,219 (Accolate) or cromolyn (Intal) in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 95 (1:part 2):Abs 990.
80. Spector S, Miller CJ, Glass M. 13 week dose response study with Accolate (zafirlukast) in patients with mild to moderate asthma. Am J Resp Crit Care Med 1995; 151 (4):A379 Abs.
81. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI, 204,219 relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151:1734-9.
82. Szczeklik A. Aspirin-induced asthma: An update and novel findings. In: Advances in Prostaglandin Thromboxane and Leukotriene Research 1994; 22:185-98.
83. Lee TH. Mechanism of bronchospasm in aspirin-sensitive asthma. Am Rev Respir Dis 1993. 148 (6) part; 1:1442-3.
84. Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing and asthma. Am Rev Respir Dis 1984; 130:1014-8.
85. Watson WTA, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91:97-101.
86. Welch PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Clinic Proc 1987; 62:125-34.